Compare · MDLN vs SGP
MDLN vs SGP
Side-by-side comparison of Medline Inc. (MDLN) and SpyGlass Pharma Inc. (SGP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SGP operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $50.91B, about 74.3x SGP ($685.0M).
- Over the past year, MDLN is down 4.8% and SGP is down 20.9% - MDLN leads by 16.1 points.
- MDLN has hit the wire 4 times in the past 4 weeks while SGP has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 5 for SGP).
PerformanceMDLN-17.99%SGP-20.91%
2026-02-06+0.00%2026-07-24
- Company
- Medline Inc.
- SpyGlass Pharma Inc.
- Price
- $38.78+3.02%
- $20.65-1.15%
- Market cap
- $50.91B
- $685.0M
- 1M return
- +7.57%
- +6.33%
- 1Y return
- -4.83%
- -20.91%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2026
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 5
Latest MDLN
- Medline strengthens California distribution network with new 1 million-square-foot facility in Perris
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
Latest SGP
- SpyGlass Pharma Appoints Shannon Treviño as General Counsel
- SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
- SpyGlass Pharma to Participate in Upcoming Investor Conferences
- SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
- SEC Form 10-Q filed by SpyGlass Pharma Inc.
- SpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- SEC Form 10-K filed by SpyGlass Pharma Inc.
- SpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update